CRISPR Therapeutics AG
Here’s whether CRISPR Therapeutics AG (CRSP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.83% over 10 days); strong 1-year return of +12.7%; 3-month momentum positive (+18.1%). Concerns: RSI 75 — overbought, elevated pullback risk. Currently 24.2% off its 52-week high. Score: +5/7.
CRSP is in a confirmed uptrend, trading above both its 50-day ($52.77) and 200-day ($53.08) moving averages. With an RSI of 75.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +12.7% compares to +20.5% for SPY (trailed the market by 7.8%). The current 24.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.